We are all very excited about Dean Robert Sullivan joining our Business Advisory Board. It is a true honor to have a business leader of his caliber join our board and assist in the development of our Cardiology Division.
San Diego, CA (PRWEB) May 02, 2013
Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert Sullivan, PhD, dean of the Rady School of Management at the University of California, San Diego (UC San Diego) has agreed to join the Company’s Business Advisory Board. Dr. Sullivan is an expert on entrepreneurship, knowledge management and operations management.
As an Advisor, Dean Sullivan’s specific focus will be Stemedica’s newly formed Cardiology Division which aims to advance Stemedica’s national and international clinical trials in chronic heart failure, acute myocardial infarct and other cardiac conditions. Within this Division, Dr. Sullivan will assist the Company as a liaison between not only the San Diego biotech and business communities, but with organizations worldwide.
As the founding dean of the Rady School of Management, Dr. Sullivan has increased the school’s brand in San Diego and throughout the world. He has successfully recruited top-tier faculty from universities such as the University of Chicago, Massachusetts Institute of Technology (MIT), New York University, Northwestern, Princeton, Stanford, the Wharton School and Yale. In 2011, Dr. Sullivan was elected vice chair-chair elect of the Association to Advance Collegiate Schools of Business (AACSB International), the premier accrediting body for business education.
Dr. Sullivan has held a variety of posts prior to joining the Rady School of Management at UC San Diego. Before coming to San Diego, he was dean of the Kenan-Flagler Business School of The University of North Carolina, Chapel Hill. From 1995 to 1997, he served as director of the University of Texas at Austin’s IC2 Institute, a nontraditional international center for research and education on innovation, creativity, capital and commercialization. Dr. Sullivan served as dean of the Graduate School of Industrial Administration at Carnegie Mellon University from 1991 to 1995. During his tenure, the school’s rankings rose dramatically. He led a reengineering of the school’s educational programs, including integrating advanced technology into the field of finance and creating experiential and international distance-learning opportunities for students. Earlier in his career, he served in a variety of posts at the University of Texas.
Dr. Sullivan holds a doctorate in operations management from Pennsylvania State University, a master’s degree in production management and quantitative methods from Cornell University and a bachelor’s degree in mathematics from Boston College.
Dr. Sullivan commented, “We are fortunate to have such a vibrant biopharmaceutical environment in the San Diego area. Stemedica represents the type of dynamic, emergent company that--with the right blend of strategy, leadership and resources--can become a great success story. The stem cell and regenerative space is growing rapidly and I look forward to contributing my experience and skills to help Stemedica take advantage of this opportunity.”
Maynard Howe, PhD, Chief Executive Officer and Vice Chairman added, “One of the traits of a knowledge-based company is knowing when to reach out to the best external resources to provide a most welcome leadership perspective. We are so very fortunate to have a leading international resource—in the presence of Dean Sullivan—right here in our San Diego community. We look forward to working with him.”
Sergey Sikora, PhD, President of Stemedica’s Cardiology Division added, “We are all very excited about Dean Robert Sullivan joining our Business Advisory Board. It is a true honor to have a business leader of his caliber join our board and assist in the development of our Cardiology Division. He has a track record of bringing business schools from the virtually unknown to world-known premier business education institutions. His experience in rapidly growing organizations will have a huge impact on our organization as well."
About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan (at) stemedica.com.